Research

Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients

Giovanni Apolone*1, Oscar Bertetto2, Augusto Caraceni3, Oscar Corli4, Franco De Conno3, Roberto Labianca5, Marco Maltoni6, Mariaflavia Nicora7, Valter Torri8, Furio Zucco9 and the Cancer Pain Outcome Research Study Group

Address: 1Laboratorio di Ricerca Traslazionale e di Outcome, Dipartimento di Oncologia, Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62, 20157 Milan, Italy, 2Oncologia Medica, Ospedale Molinette, C.so Bramante 88, 10126 Turin, Italy, 3Unità Operativa Cure Palliative, Istituto Nazionale dei Tumori, Via Venezian 1, 20123 Milan, Italy, 4Unità Operativa Cure Palliative, Istituti Clinici di Perfezionamento, P.O. "Vittore Buzzi", Via Castelvetro 32, 20154 Milan, Italy, 5Onco Medica, Ospedali Riuniti di Bergamo, Largo Barozzi 1, 24100 Bergamo, Italy, 6Hospice Forlimpopoli, ASL Forlì Cure Palliative Via Duca D'Aosta 33, 47034 Forlimpopoli (FC), Italy, 7Direzione Medica, Grunethal-Formenti, Via Correggio 43, 20149 Milan, Italy, 8Laboratorio di Ricerca Clinica Oncologica, Dipartimento di Oncologia, Istituto di Ricerche Farmacologiche "Mario Negri", Via Eritrea 62, 20157 Milan, Italy and 9Hospice Garbagnate, Cure Palliative AO Salvini Viale Forlanini, 121 20024 Garbagnate Milanese (MI), Italy

Email: Giovanni Apolone* - apolone@marionegri.it; Oscar Bertetto - obertetto@molinette.piemonte.it; Augusto Caraceni - augusto.caraceni@istitutotumori.mi.it; Oscar Corli - o.corli@virgilio.it; Franco De Conno - franco.deconno@istitutotumori.mi.it; Roberto Labianca - rlabianca@ospedaliriuniti.bergamo.it; Marco Maltoni - malto.ma@tin.it; Mariaflavia Nicora - mariaflavia.nicora@formenti.it; Valter Torri - torri@marionegri.it; Furio Zucco - fzucco@aogarbagnate.lombardia.it

* Corresponding author

Published: 02 February 2006

Abstract

Background: Management of pain related to advanced or metastatic cancer, although the availability of several pharmacological and non-pharmacological interventions and the existence of well-known guidelines and protocols, is often difficult and inadequate. Evidence of the relative effectiveness of current options for treating cancer pain from comparative randomized studies is scanty.

Methods: In the context of a wider project, a multicenter, open label, prospective Outcome Research study will be launched in Italy in 2006 to investigate the epidemiology of cancer pain and of its treatments, the quality of analgesic-drug therapy and the effectiveness of alternative analgesic strategies in a large, prospective, unselected cohort of cancer patients using the state-of-the-art of patient-reported-outcomes. About 100 Italian centers will recruit 2500 patients with advanced/progressive/metastatic cancer with pain (related to the cancer disease) requiring analgesic treatments. Each center is expected to recruit 25 consecutive and eligible patients during the study inception period. Approximately two months will be allowed for subject recruitment and enrollment. Subject evaluation and follow-up will be for 3 months. The effect on outcomes of various therapeutic analgesic options administered by physicians, given the observational approach where patients are not assigned at random to different treatments, will be compared using the propensity score approach, allowing the adjustment for treatment selection bias. Later, after the launch of the observational study and on the basis of results, in specific subsamples of patients and in select centers of the network, a Randomized Controlled Trial will be carried out to formally compare the efficacy of alternative analgesic strategies, with particular emphasis on oral morphine (as comparator) and buprenorphine patch (as experimental arm). Results from the outcome (cohort) and experimental (Randomized Controlled Trial) studies will ensure both the external and internal validity.
**Background**

Pain afflicts most cancer patients, mainly in the advanced and metastatic phase of the disease [1]. Recent reviews of published literature suggest that the prevalence of pain in advanced cancer is about 70% with ample variations according to the cancer type and disease stage [2].

Despite the existence of published and well-known guidelines for cancer pain management recommended by the World Health Organization (WHO) and effective treatments are available for 70–90% of cases [3], under-treatment is well documented and large proportions of cancer patients (reaching in some evaluations 40%) remain intentionally under-treated [4] for several reasons, often conceptualized in terms of barriers related to health care provider, patient, family, institution and society [5]. The most frequent cause of under-treatment is usually considered misconceptions about opioids [6].

Evidence about pain prevalence, drug utilization and treatments effectiveness in cancer patients are scanty, most deriving from placebo trials, with very few comparative studies in large and well characterized cohorts of cancer patients. Furthermore, it is not available in medical literature any large parallel randomized controlled trial conducted in advanced cancer patients suffering from severe pain (step 3 in the WHO’s pain ladder), comparing any alternative opioids to oral morphine [7-10].

The general picture that derives from the analysis of experiences carried out in international settings does apply to Italy also, with some peculiarities: a) Opioids consumption is ranked among the lowest in Europe until 2000, with some improvements at least in terms DDD/100,000 people after the introduction of new opioids in the list of reimbursable drugs (transdermal fentanyl and morphine syrup) in 2000 [11]. b) Until January 2005, when a new bill was introduced at national level, no WHO-step II analgesic products were available in the list of reimbursable drugs in most of Italian regions, as well as some “strong” WHO-step III opioids, making it difficult for physicians the appropriate prescription of drugs and creating variability in drugs utilization across different Italian regions. c) A non appropriate use of transdermal fentanyl can be suspected, as too many patients received it as first option, although recommended only when oral morphine is inadequate [12].

A multidisciplinary Advisory Board of experts in the field of cancer and pain treatments from Industry, Scientific Societies and Patients Associations was convened by the Mario Negri Institute on November 2003 to discuss the quality of pain management in cancer patients in Italy and, eventually, to recommend possible ameliorative educational and research strategies. Member of the Boards highlighted the lack of and the need for new empirical evidence about the epidemiology and the effectiveness of available therapeutic strategies, and called for a prospective program of research aimed at making available to treating physicians, patients and families valid information about pain management in cancer. Two main lines of activities were identified as necessary: information and education activities addressed to physicians, care givers and patients/citizens, and prospective data collection to document patterns of care and outcomes.

Operationally, some working groups met several times during 2004, identified a selected sample of about 100 centers treating cancer patients with advanced/metastatic disease and pain that could be potentially eligible for a prospective study, and planned 3 types of activities to be implemented during the following 3 years (2005–2007): a) information and education: a prototype of educational course for professionals (physicians and nurses) has been assembled and tested on a sample of participants (through a residential course approved by the Italian Committee for Medical Continuing Education with 26 and 33 credits for physicians and nurses, respectively); a critical appraisal of information available in the web (Internet) was also carried out with the preparation and publication of a meta-site that facilitates the use of selected (internet) resources for people interested and/or involved in issues related to cancer pain [13]; b) drug utilization and appropriateness: an evaluation of the volume and quality of prescriptions of analgesic drugs in a large administrative data base in collaboration with local Italian Health Authorities has been started to test the feasibility of the approach in a wider context (regional); c) a prospective, multicenter, nationwide effectiveness study to test the effect of different and alternatives analgesic strategies (such as oral morphine, fentanyl and buprenorphine patches, etc) on patient-reported-outcomes.

The above initiatives are fully described elsewhere [14,15]. In the present paper we provide details about the prospective multicenter study, involving more than 100 Italian centers that has the objective to assess the epidemiology and quality of different and alternatives analgesic strategies (such as oral morphine, fentanyl and buprenorphine patches, etc) and their effect on patient-reported-outcomes. Results are expected by the end of 2006.

**Study rationale**

Evidence of the relative effectiveness of current options for treating cancer pain from comparative randomized studies is scanty. This study will investigate the epidemiology of cancer pain and of its treatments, the quality of analgesic-drug therapy and the effect of alternative analgesic strategies in a large, prospective, unselected cohort of cancer patients using the state-of-the art of patient-reported-
outcomes. Later, after the launch of the observa-
tional study and on the basis of results, in specific sub-
samples of patients, in select centers, a Randomized
Controlled Trial (RCT) will be carried out to formally
compare the efficacy of alternative analgesic strategies,
with particular emphasis on oral morphine as comparator
and buprenorphine patch as experimental arm. Results
from the outcome and experimental studies will ensure
both the external and internal validity. This kind of
approach - a comprehensive cohort design study where all
participants are followed up regardless of their randomi-
ization status, and outcomes of people who participated in
the RCT can be compared with those who participated in
the cohort study to assess their similarities and differences
- is ideal for trials in which large proportions of eligible
individuals are likely to be not entered in the RCT [14,16-
18].

**Objectives**

**Primary objective**
- To describe the characteristics of a large sample of cancer
  patients in terms of case mix (patients characteristics),
  pattern of care (pharmacological and non-pharmacologi-
cal treatments) and relevant efficacy (analgesic and other
  patient-reported outcomes (PRO) outcomes such satisfac-
tion, quality of life measures) and safety outcomes
  (generic, disease and treatments specific).

- To assess the quality of analgesic treatments in terms of
  congruence between patients’ reported level of pain
  (intensity) and the potency of the prescribed analgesic
drug (according to the WHO analgesic ladder) [19].

**Secondary objectives**
The database will be used to evaluate the effects of various
therapeutic analgesic options administered by physicians

to patients. Given the observational setting, outcomes of
subjects who were not assigned at random to different
treatments will be compared using the propensity score
approach, allowing the adjustment for treatment selection
bias [20], as recently done in some large observational
population studies [21,22]. The reference group will be
those patients treated with oral morphine. The propensity
analyses will be carried out:

- To evaluate the effectiveness of treatment regimens on
  pain intensity and patient-reported quality of life

- To evaluate the effect of treatment regimens on patient-
  reported satisfaction

- To evaluate the safety profile (adverse and side effects) of
  alternative treatment regimens

**Methods**

**Study design**
This study will be designed as a multi-center, open-label,
observational non-interventional trial in at least 100 cent-
ers, in Italy. Approximately 25 subjects will be enrolled in
each center. Subjects will be treated by physicians accord-
ing to the usual practice (standard of care) and followed
over time using standardized methods and forms to make
possible a valid and reliable description of case-mix, pat-
tern of care and outcomes. Subjects will be monitored to
evaluate the analgesic effects for 28 days (4 weeks) and
then with a simplified scheme for further 8 weeks.

**Scheduled study specific assessments will be done as follows (Table 1)**
- Baseline assessment (First visit).

| Procedure                      | Screening | Telephone contact | Telephone contact | Visit Day 4 | Visit Day 7* | Visit Day 14* | Visit Day 21* | Visit Day 28* | Final Visit |
|--------------------------------|-----------|-------------------|-------------------|-------------|-------------|-------------|-------------|-------------|-------------|
| Informed consent              | x         | -                 | -                 | -           | -           | -           | -           | -           | -           |
| Eligibility criteria          | x         | -                 | -                 | -           | -           | -           | -           | -           | -           |
| Study registration            | x         | -                 | -                 | -           | -           | -           | -           | -           | -           |
| Medical history               | x         | -                 | -                 | -           | -           | -           | -           | -           | x           |
| Physical examination          | x         | -                 | -                 | x           | x           | x           | x           | x           | x           |
| Analgesic consumption         | x         | -                 | -                 | -           | -           | -           | -           | -           | x           |
| Pain assessment (BPI)         | x         | x                 | x                 | x           | x           | x           | x           | x           | x           |
| Symptoms and Side effects assessment | x     | x                 | x                 | x           | x           | x           | x           | x           | x           |
| Patient global assessment     | x         | -                 | -                 | -           | x           | x           | x           | x           | x           |
| Physician global assessment   | x         | -                 | -                 | x           | x           | x           | x           | x           | x           |
| HRQOL                          | x         | -                 | -                 | -           | x           | x           | x           | x           | x           |

*mandatory
- Telephone contacts 24 and 48 hours after the inclusion (facultative).

- Visit at day 7,14,21,28.

- Final complete assessment at month 3 (12 weeks from inclusion and 8 from last complete evaluation) regarding patients’ (analgesic and non-analgesic) outcomes and vital status; a summary of treatments delivered during the period is also planned.

**Subject population**
All patients, either new cases or already followed-up at the participating centers, with eligible (advanced or metastatic) solid cancers and with pain (related to cancer disease) requiring any treatment are eligible to be included during the study inception period.

**Study period and number of cases per-center**
Each center is expected to recruit 25 consecutive and eligible patients during the study inception period.

Approximately two months will be allowed for subject recruitment and enrollment. Subject evaluation and follow-up will be for 3 months.

**Study conduct and supervision**
In order to be able to conduct and monitor the progress of the trial for the patients' safety and according to the World Medical Association Declaration of Helsinki and the European and Italian Good Clinical Practice guidelines, as well as to establish and guide the Group publication policy, several Committees, Boards and Groups have been assembled and organized in a pre-planned Trial Structure and Organization, with explicit guidance for its functioning. Basically, 4 hierarchical bodies will be created: an Advisory Board, a Steering Committee, a Protocol Writing Committee and a Project Management Group (Appendix 1 [see Additional file 1]). If necessary, a Committee for Ancillary Studies (CAS) will be also activated.

**Entry criteria**
All patients seen at the participating centers during the study inception period will be screened, and if considered eligible included, registered and monitored over time. After a check of the eligibility and inclusion in the study, the investigator will assign treatments to patients according to the standard practice (usual care). In the case of prescription of WHO step-II and -III drugs, appropriate strategies will be recommended to reach the adequate individual pain control, with particular attention to titration, identification and management of side effects.

**Eligibility (inclusion) criteria**
The study will include patients:
1. with diagnostic (histological or cytological) evidence of advanced/progressive/metastatic solid tumor;
2. with pain, any degree of intensity (assessed on a numerical scale from 0 to 10 by asking the patient to rate the average intensity of his/her pain over the last 24 hours), related to cancer, requiring analgesic treatment or already on analgesic treatment;
3. with age $\geq$ 18 years;
4. with a life expectancy of greater than 1 month;

**Exclusion criteria**
A subject must not meet any of the following exclusion criteria to be eligible in the study:
1. the subject is less than 18 years of age;
2. the subject is participating in other research projects that conflict or may confound the results of the present study;
3. the subject is unwilling or unable to provide a valid consent for the participation;
4. the subject has some medical conditions, including psychiatric/mental illness, severe senile or Alzheimer’s dementia, substance abuse, deemed by the Investigator to be likely to interfere with participation and compliance with the study protocol;
5. the subject cannot guarantee regular follow-up visits for logistic or geographic reasons.

**Study medications (drugs supply) and other medical procedures**
Pharmacological and non-pharmacological interventions, prescribed by physicians in the context of their best practice for cases included in the prospective cohort study are provided free as in all centers they are standard care for patients requiring analgesic treatments for pain control, according to each center and investigator policy. In the case a RCT will be activated in the context of the study, drugs compared in the RCT part of the study will be furnished by the Sponsor(s).

All medications must be documented on the CRF.

**Informed consent**
Subjects must be able to provide valid written consent, approved by the local Ethics Committee centrally by the study coordinating center.
Subject enrollment
After consent is obtained, a subject will be enrolled when he/she meets all the inclusion criteria and none of the exclusion criteria. A sequential site-patient number will be assigned.

Baseline Assessment
After enrollment/inclusion, the following screening assessments will be performed and recorded: a) medical history including past cancer history, b) physical examination, c) recording of medications and recent therapies, including analgesic consumption, d) pain assessment using the Brief Pain Inventory (BPI), e) symptoms and side effects assessment, f) patient and physician global assessment (PGA), g) patient’s self-reported health-related quality-of-life (HRQOL).

Follow-up assessments
According to the flow-chart (Table 1), some evaluations are recommended and others are compulsory. In addition to the first baseline assessment, the following evaluations are mandatory: day 7, 14, 21, 28.

Final (end-of-study) visit
At week 12 (3 months after the inclusion) a complete reassessment is required: a) medical history including past cancer history, b) physical examination, c) recording of medications and recent therapies, including analgesic consumption, d) pain assessment using the BPI, e) symptoms and side effects assessment, f) patient and physician global assessment, g) patient’s self-reported health-related quality-of-life.

Pain assessment
Pain will be assessed with the BPI [19,23,24] which will be administered at baseline, at day 7, 14, 21, 28 and at week 12 (3 months) when patients will attend regular visits at the center or during admission or at home depending on the setting of care (outpatient clinic, hospice, hospital unit, home care).

Quality of analgesic care assessment
The quality of analgesic treatments will be cross-sectionally assessed in terms of congruence between the patients’ reported level of pain (intensity) and the potency of the prescribed analgesic drug (according to the WHO analgesic ladder). Operationally, self-reported pain intensity (from the BPI) and the level of most potent analgesic prescribed (from the CRF) will be combined to assemble a Index of Pain Management (IPM) that ranges from -3 (a patient with severe pain receiving no analgesic drugs) to +3 (a patient receiving morphine or an equivalent drug an reporting no pain) [19]. Data collected longitudinally will be used to test the validity and yield of other dynamic approaches to assess the quality of analgesic care at individual level.

Quality of life and other relevant patient reported outcomes
Quality of life, satisfaction measures and symptoms/side effects check-lists will be administered to patients when planned during the follow-up [25-27].

Information about all pain medications and number of rescue doses assumed by patients will be also recorded in the CRF.

Safety issues
All adverse events, serious and non-serious, as well as generic, disease and treatment specific symptoms, encountered during the clinical study will be reported on the appropriate page of the CRF.

Sample size estimates
According to data available from the literature and to preliminary results from an ongoing observational Italian study [28], we may assume that 100 centers during a inception (recruitment) period of 2 months can include and evaluate about 2,500 eligible cases. Half of them will be already receiving a WHO-step III treatment. Most (60%) of the remaining 1250 will eventually need a WHO-Step III analgesic drug (750) during the longitudinal evaluation period.

Overall, considering the inception and the longitudinal evaluation, the entire duration of the study is estimated around 5 months. At the moment, more than 160 centers accepted to participate and 130 have successfully carried out a pilot phase of the study to test the study feasibility (Appendix 2 [see Additional file 2]).

Data analysis and statistics
According to the first main objective of the study (i.e., to describe the characteristics of cancer patients in terms of patients characteristics, pharmacological and non-pharmacological treatments and relevant analgesic and other PRO outcomes such as satisfaction, quality of life, generic, disease and treatments specific side effects), all patients enrolled in the study and eligible will be included in the statistical descriptive analyses. To avoid and minimize the impact of missing data, a bias that may be present in the case of using patient-reported measures as principal outcomes/endpoints [29-32], particularly when patients discontinue study treatment, specific procedures to treat missing items will be used, such as the last observation carried forward -LOCF. Data will be analyzed using either parametric and non-parametric statistical tests. When appropriate, for example for the weekly pain ratings scales, scores will be analyzed using repeated analyses of
variance to analyze and separate the effects of treatments and time and test the interaction between the two, as well [33].

As to the assessment of the quality of analgesic care, the adequacy of pain management will be assessed firstly using the IPM, an index assembled by grouping with explicit and pre-planned rules patient with different intensity of pain and level of analgesic therapies [19]. Although IPM is not accurate for prescribing drug to an individual, it provides a rough estimate of how pain is treated in the population. According to the literature, each patient will be classified into one of seven mutually exclusive levels of care (from -3 to +3) and appropriate univariate and multivariate analyses will be carried out on the whole sample and on relevant sub-groups to screen predictors of poor analgesic care and to identify patients at greater risk of under-medication. Data collected over time will be used to develop and test new methods to assess quality of analgesic care that may be used at individual (single case) level.

As to the secondary objective of the study (i.e., to evaluate the effects of various therapeutic analgesic options administered by physicians to patients), given the non-randomized design the propensity score approach [20-22] will be used to balance the covariates in the groups and thus reduce the bias produced by the lack of randomization. Briefly, in all 3 comparisons planned by protocol (oral morphine vs fentanyl patch, oral morphine vs buprenorphine patch, fentanyl vs buprenorphine), a comparison specific propensity scores will be estimated. The propensity score method implies a comprehensive collection of information known to be causally associated with the choice of the treatments, then the production of a propensity score (the conditional probability of exposure to a treatment given the observed covariates) using standard statistical models such as logistic regressions to predict the treatment (for example, the choice of morphine in eligible patients), eventually the comparison of outcomes (for example, pain intensity) by matching or stratifying patients according to the value of the propensity scores.

**Study endpoints**
The Study will collect, describe and assess a vast array of outcomes measures related to pain and to its impact on patients’ life. Some of these measures will be collected and reported by physicians and other directly by patients.

**Pain related outcomes**
The predefined primary outcome measurement is the pain intensity over the first weeks, assessed with four questions from the BPI, that will be used either individually or after the computation of their mean, as indicated by developers [19,23,24]. The relevant endpoint is the reduction in worst and average pain score of ≥ 2 points (pain intensity difference, PID, ≥/≤ 2) at week 4 (day 28 from inclusion) over baseline.

**Other endpoints**
Escape/Rescue pain medications: counts of rescue/escape medications taken to control pain from inclusion to week 4 (day 28 from inclusion).

Adequacy of analgesic-drug therapy: Patient Management index (PMI), categorized in a binary variable according to negative (indicating inadequate analgesic care) and positive (conservative indicator of acceptable treatment) levels.

Other patient-reported endpoints: HRQOL, Satisfaction with (drugs) treatment, rate and severity of symptoms, adverse and side effects.

**Ethical approval and publication policy**
Before entering patients into the cohort study, clinicians/investigators must ensure that the Protocol has received clearance from the Local Research Ethics Committee (L-REC). The patients’ consent to participate in the studies should be obtained after a full explanation has been given. Particular attention should be given to explaining the purposes, manner of the management and use of the patients’ data from questionnaires and diaries. The right of the patient to withdraw from the studies in any time, without giving reasons, must be respected.

The responsibility for drafting the manuscripts related to the analyses described in this protocol will lie with the WPC whose members will be the primary Authors. At least one representative from high-recruiting centers will be included among the co-authors, and all participants will be acknowledged in the Appendices. All authors should review and approve the manuscript before submission. At least two papers are expected: the first reporting on the results of the “epidemiological” part of the study, including a description of patients’ characteristics in terms of baseline socio-demographic and clinical variables, pattern of care and main outcomes, and a discussion of the feasibility of this kind of approaches in the specific setting, the second about the effects (effectiveness) of treatments on patients (and physicians) reported outcomes.

**Additional material**

**Additional File 1**
Appendix 1. Advisory Board, Steering Committee, Protocol Writing Committee and Project Management Group
Click here for file [http://www.biomedcentral.com/content-supplementary/1477-7525-4-7-S1.doc](http://www.biomedcentral.com/content-supplementary/1477-7525-4-7-S1.doc)
Acknowledgements

The study was supported by Grunenthal-Formenti (Italy) with a unrestricted educational grant.

References

1. Cherny N. The management of cancer pain. Cancer J Clin 2000, 50:70-116.
2. Hearn J, Higginson IJ. Cancer pain epidemiology: a systematic review. In Cancer Pain, Assessment and Management Edited by: Bruera ED, Portenoy RK. Cambridge University Press; 2003.
3. WHO Cancer Pain Relief: with a Guide to Opioid Availability. WHO, Geneva, 1996. WHO, Geneva; 1990.
4. Cohen MZ, Easley MK, Ellis C, Hughes B, Ownby K, Rashad BG, Rudy M, Taft, E. Westbrooks JB: A Cancer Pain Management and the JCAHO’s Pain Standards. An Institutional Challenge. J Pain Symptom Manage 2003, 25:519-527.
5. Ripamonti C, De Conno F, Blumhuber H, Ventafridda V: Morphine for relief of cancer pain. Lancet 1996, 347:1262-1263.
6. Zeno M, Wilkens-Stumpf A: Opiophobia and cancer pain in Europe. Lancet 1993, 341:1075-1076.
7. Ahmedzai S, Brooks D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy and quality of life. J Pain Symptom Manage 1997, 13:254-261.
8. Srid R, Griesinger N, Likar R: Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomised, double blind, placebo controlled trial. Clin Therapeutics 2003, 25:150-168.
9. Böhm K, Likar R: Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomised, double-blind, placebo-controlled study. Pain Clinic 2003, 15:193-202.
10. Farar JT, Halpern SD: Understanding clinical trials in pain research. In Cancer Pain, Assessment and Management Edited by: Bruera ED, Portenoy RK. Cambridge University Press; 2003.
11. De Conno F, Ripamonti C, Brunelli C: Opioids purchase and expenditures in nine western European countries: are we killing off morphines? Paliatt Med 2005, 19:79-184.
12. Chinellato A, Terrazzani G, Walley T, Giusti P: Opioids on Italy: is marketing more powerful than the law? Lancet 2003, 362:78.
13. PAIN.CARE. [http://www.paincare.it]
14. Apolone G, Mosconi P, Colombi P, Tamburini M: Il dolore nel paziente con cancro: un progetto di ricerca. Ricerca & Pratca 2004, 20:137-143.
15. PROGETTO "IL DOLORE NEL PAZIENTE CON CANCRO" [http://crc.marionegri.it/cancerpain]
16. Judd A. Randomized Controlled Trials. A user's guide. BMJ Books 1998.
17. Brewin CR, Bradley C: Patient preferences and randomised clinical trials. BMJ 1989, 299:684-685.
18. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S, Laine C, Marusic A, Overbeke AJ, Schroeder TV, Sox HC, Van Der Weyden MB, International Committee of Medical Journal Editors: Clinical trials registration. a statement from the International Committee of Medical Journal Editors. New Engl J Med 2004, 351:1290-1291.
19. Cleeland CS, Gonin R, Hatfield AK, Edmonson JH, Blum RH, Stewart JA, Pandya KJ: Pain and its treatments in outpatients with metastatic cancer. N Engl J Med 1994, 330:592-596.
20. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127:757-763.
21. Hawkins T, Lamont EB: Effectiveness of adjuvant fluorouracil in clinical practice. A population-based cohort study of elderly patients with stage III colon cancer. J Clin Oncol 2002, 20:3992-3998.
22. Apolone G, Cavuco S, Torri V, la Vecchia C: Effectiveness of adjuvant fluorouracil in elderly colon cancer patients. The internal and external validity of non randomized research design. J Clin Oncol 2003, 21:1892-1897.
23. Cleeland CS: Measurement of pain by subjective report. Edited by: Chapman CR, Loeser JD. Issue in pain measurement. New York: Raven Press; 1989.
24. Caraceni A, Mendoza TR, Mencaglia E, Baratella C, Edwards K, Forjaz MJ, Martini C, Serlin RC, de Conno F, Cleeland CS: A validation study of an Italian version of the Brief Pain Inventory (Breve Questionario per la Valutazione del Dolore). Pain 1996, 65:87-92.
25. Groenwald M, Petersen MA, Aaronson NK, Arraras JI, Blazey JM, Bottomley A, Fayers PM, de Graeff A, Hammerlid E, Kaasa S, Sprangers MA, Börner JB, for the EORTC Quality of Life Group: The development of the EORTC QLQ-C15-PAL: A shortened questionnaire for cancer patients in palliative care. Eur J Cancer 2006, 42:55-64.
26. Viscusi ER, Reynolds L, Chung F, Atkinson LE, Khanna S: Patient-controlled transdermal fentanyl hydrochloride vs intravenous morphine pump for postoperative pain: a randomized controlled trial. JAMA 2004, 291:1333-1341.
27. Sweeney C, Bruera ED: Opioids side effects and management. In Cancer Pain, Assessment and Management Edited by: Bruera ED, Portenoy RK. Cambridge University Press; 2003.
28. Corli C, Pizzuto M: Il trattamento del dolore nei malati oncolo-gici seguiti in setting di cure non specificatamente palliative. OICP, Progetto 2003. GPA-Net Milano 2004.
29. FDA-Guidance for Industry: Patient-reported outcome measures: Use in medical product development to support labeling claims - Draft guidance. 2006 [http://www.fda.gov/cder/guidance/5460dft.pdf].
30. Farrar JT, Portenoy RK, Berlin JA, Kinman JL, Stroom BL: Defining the clinically important differences in pain outcomes measures. Pain 2000, 88:287-294.
31. Farrar JT, Young Jr Jr, LaMoreaux L, Werth JL, Poole RM: Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 2001, 94:149-158.
32. Caraceni A, Galbiati A, Brunelli C, Gorni G, Martini C, Zecca E, De Conno F: Cancer patient compliance in the self-administration of pain assessment. J Pain Symptom Manage 2004, 27:417-424.
33. Kleinbaum DG, Kupper LL, Muller KE: Applied regression analysis and other multivariable methods. PWS-Kent Publishing Company; 1988.

Publish with BioMed Central and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK

Your research papers will be:
- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp